Literature DB >> 1548998

Effects of exercise training on men seropositive for the human immunodeficiency virus-1.

L W Rigsby1, R K Dishman, A W Jackson, G S Maclean, P B Raven.   

Abstract

We examined the effects of chronic exercise on fitness and immune status in Caucasian males (34.9 +/- 5.6 yr) diagnosed by Western blot as seropositive for the HIV-1 virus. The exercise regimen involved 12 wk of 1 h sessions 3 d.wk: 20 min of cycle exercise at 60-80% HRreserve was followed by 35 min of strength and flexibility training. After matching subjects on health status (modified Walter Reed criteria), subjects (N = 37) were randomly assigned to exercise or a counseling control condition. Changes in strength, responses to the YMCA cycle test, and serum lymphocytes were tested by MANOVA in a condition (exercise or counseling)-by-time (pretest, posttest) design with repeated measures on time. Results indicated significant (P less than 0.001) group-by-time interactions for strength (N.m) (chest press and leg extension) and for HR (beats.min-1) and total time (TT) on the cycle test at 150 W. Strength and TT increased and HR decreased in the exercise condition, while control subjects did not change. Total leukocyte, lymphocyte, CD4+, and CD8+ cell counts, and the CD4+/CD8+ ratio were statistically unchanged for each condition. We conclude that HIV-1+ men, including those symptomatic for AIDS-related complex, can experience significant increases in neuromuscular strength and cardiorespiratory fitness without changes in lymphocyte phenotypes or clinical diagnosis when the exercise regimen is prescribed and monitored in accordance with ACSM guidelines for healthy adults.

Entities:  

Mesh:

Year:  1992        PMID: 1548998

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  20 in total

1.  HIV and aerobic exercise. Current recommendations.

Authors:  W W Stringer
Journal:  Sports Med       Date:  1999-12       Impact factor: 11.136

2.  Social cognitive and physical health determinants of exercise adherence for HIV-1 seropositive, early symptomatic men and women.

Authors:  R M Pavone; K F Burnett; A LaPerriere; F M Perna
Journal:  Int J Behav Med       Date:  1998

3.  Aerobic and resistance exercise training effects on body composition, muscular strength, and cardiovascular fitness in an HIV-1 population.

Authors:  C L Lox; E McAuley; R S Tucker
Journal:  Int J Behav Med       Date:  1996

Review 4.  Exercise and immune function. Recent developments.

Authors:  D C Nieman; B K Pedersen
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

Review 5.  Evaluating the Effectiveness of Physical Exercise Interventions in Persons Living With HIV: Overview of Systematic Reviews.

Authors:  Emiko Kamitani; Theresa Ann Sipe; Darrel H Higa; Mary M Mullins; Jesus Soares
Journal:  AIDS Educ Prev       Date:  2017-08

Review 6.  Exercise and human immunodeficiency virus (HIV-1) infection.

Authors:  D Lawless; C G Jackson; J E Greenleaf
Journal:  Sports Med       Date:  1995-04       Impact factor: 11.136

Review 7.  Human immunodeficiency virus infection, exercise and athletics.

Authors:  L H Calabrese; A LaPerriere
Journal:  Sports Med       Date:  1993-01       Impact factor: 11.136

Review 8.  The benefits of exercise training for quality of life in HIV/AIDS in the post-HAART era.

Authors:  Joseph T Ciccolo; Esbelle M Jowers; John B Bartholomew
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Physical activity and health outcomes among HIV-infected men who have sex with men: a longitudinal mediational analysis.

Authors:  Aaron J Blashill; Kenneth H Mayer; Heidi Crane; Jessica F Magidson; Chris Grasso; W Christopher Mathews; Michael S Saag; Steven A Safren
Journal:  Ann Behav Med       Date:  2013-10

10.  Effectiveness of aerobic exercise for adults living with HIV: systematic review and meta-analysis using the Cochrane Collaboration protocol.

Authors:  Kelly K O'Brien; Anne-Marie Tynan; Stephanie A Nixon; Richard H Glazier
Journal:  BMC Infect Dis       Date:  2016-04-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.